Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

821 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
van Leth F, Huisamen CB, Badaro R, Vandercam B, de Wet J, Montaner JS, Hall DB, Wit FW, Lange JM; 2NN Study Group. van Leth F, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300. J Acquir Immune Defic Syndr. 2005. PMID: 15735447 Clinical Trial.
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Montaner JS, Cahn P, Zala C, Casssetti LI, Losso M, Hall DB, Wruck J, McDonough M, Gigliotti M, Robinson PA; 1100.1286 Study Team. Montaner JS, et al. J Acquir Immune Defic Syndr. 2003 May 1;33(1):41-6. doi: 10.1097/00126334-200305010-00007. J Acquir Immune Defic Syndr. 2003. PMID: 12792354 Clinical Trial.
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. Calmy A, et al. Among authors: montaner js. Antivir Ther. 2009;14(7):931-8. doi: 10.3851/IMP1418. Antivir Ther. 2009. PMID: 19918097
Treatment as prevention--where next?
Hull M, Lange J, Montaner JS. Hull M, et al. Among authors: montaner js. Curr HIV/AIDS Rep. 2014 Dec;11(4):496-504. doi: 10.1007/s11904-014-0237-5. Curr HIV/AIDS Rep. 2014. PMID: 25384357 Free PMC article. Review.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Nelson M, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. J Acquir Immune Defic Syndr. 2005. PMID: 16280694 Clinical Trial.
821 results